<DOC>
	<DOCNO>NCT00792142</DOCNO>
	<brief_summary>RATIONALE : Bortezomib thalidomide may stop growth multiple myeloma block blood flow cancer . Bortezomib may also stop growth cancer cell block enzymes need cell growth . Giving bortezomib together thalidomide dexamethasone may kill cancer cell remain high-dose melphalan stem cell transplant patient multiple myeloma . PURPOSE : This phase II trial study side effect give bortezomib together thalidomide dexamethasone melphalan stem cell transplant see well work treat patient stage I-III multiple myeloma .</brief_summary>
	<brief_title>Bortezomib , Thalidomide , Dexamethasone After Melphalan Stem Cell Transplant Treating Patients With Stage I-III Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess feasibility toxicity maintenance therapy sequential bortezomib , thalidomide , dexamethasone high-dose melphalan autologous peripheral blood stem cell transplantation patient multiple myeloma . - To assess whether administration sequential bortezomib , thalidomide , dexamethasone improve progression-free survival patient . Secondary - To assess whether administration sequential bortezomib , thalidomide , dexamethasone increase complete remission rate duration response patient . - To assess impact maintenance therapy sequential bortezomib , thalidomide , dexamethasone transplantation overall survival patient . - To evaluate influence cytogenetic abnormality ( e.g. , chromosome 13 deletion , 14 q32 abnormality , [ 4 ; 14 ] , chromosome 1 q21 amplification , chromosome 17 deletion ) outcome perform conventional cytogenetic study fluorescence situ hybridization ( FISH ) study baseline post-transplant bone marrow specimen . OUTLINE : - High-dose melphalan autologous peripheral blood stem cell transplantation ( PBSCT ) : Patients receive high-dose melphalan IV 30 minute day -2 -1 undergo autologous PBSCT day 0 . Patients receive filgrastim ( G-CSF ) IV subcutaneously begin day 5 continue blood count recover . - Maintenance therapy : Beginning 4-8 week transplantation , patient receive bortezomib IV day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients also receive oral dexamethasone day 1-4 ; treatment dexamethasone repeat every month 12 month absence disease progression unacceptable toxicity . Beginning 2 week completion bortezomib , patient receive oral thalidomide daily disease progression . Patients complete FACT-GOG neurotoxicity questionnaire periodically . Bone marrow sample collect baseline post-transplant cytogenetic analysis FISH .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Multiple Myeloma patient symptomatic disease , stage II III diagnosis progressive stage I require chemotherapy and/or radiation therapy ( SalmonDurie classification ) , eligible tandem transplant study use TMI ; previous radiation eligibility criterion ; documentation disease stag SalmonDurie classification International Staging System ( ISS ) require Patients nonsecretory myeloma measurable serum freelight chain protein Freelite test measurable disease soft tissue myeloma A minimum 4 x 10^6 CD 34 Positive cell/kg harvest A Karnofsky performance status ( KPS ) &gt; = 70 % require unless KPS impair due bone disease No contraindication collection minimum 4 x 10^6 CD34+ cells/kg apheresis All patient must sign voluntary , informed consent accordance institutional federal guideline Bilirubin = &lt; 1.5 mg/dl Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvate transaminase ( SGPT ) &lt; 2.5 x upper limit normal Creatinine clearance &gt; = 40cc/min Absolute neutrophil count &gt; 1000/ul Platelet count &gt; 100,000/ul Cardiac ejection fraction &gt; = 45 % multigated acquisition ( MUGA ) scan and/or echocardiogram Diffusing capacity lung carbon monoxide ( DLCO ) &gt; = 50 % predict low limit Human immunodeficiency virus ( HIV ) antibody test negative No medical , psychosocial problem opinion primary physician principal investigator would place patient unacceptably high risk treatment regimen Presence peripheral neuropathy &gt; = grade II Patients evidence disease progression ( &gt; = 25 % increase M protein ) bortezomib thalidomide therapy prior transplant Pregnant nursing woman , well woman child bear age , unwilling use dual method contraception men unwilling use condom Patients history hypersensitivity bortezomib , boron mannitol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>